Table 4.

OR of previous COVID-19 and adverse effects after mRNA BNT162b2 vaccine (n =278)

Adverse effect*		Dose 1 OR (IC 95%)	p	Dose 2 OR (IC 95%)	p
Low grade fever (<38ºC)		2.96 (1.08-8.04)	0.033	0.66 (0.30-1.45)	0.303
Fever >38ºC & < 39ºC		0.85 (0.10-7.40)	0.880	0.13 (0.02-0.94)	0.043
Asthenia		2.48 (1.32-4.67)	0.005	2.48 (1.32-4.67)	0.005
Headache		2.80 (1.46-5.38)	0.002	0.83 (0.44-1.56)	0.565
Dysthermia		4.36 (2.11-9.00)	<0.0001	0.77 (0.40-1.47)	0.425
Cough		1.29 (0.34-4.86)	0.71	0.16 (0.04-0.69)	0.014
Myalgia		5.69 (2.35-13.78)	<0.0001	0.97 (0.50-1.88)	0.932
Arthralgia		4.82 (1.72-13.52)	0.003	1.04 (0.47-2.31)	0.925
Antipyretic use		3.46 (1.71-6.99)	0.001	0.89 (0.47-1.69)	0.721
Post-vaccine limitation
None (0) Very Mild (1) Mild (2) Moderate (3) Severe (4) Very Severe (5)		1 2.28 (1.04-5.01) 2.35 (0.84-6.59) 6.28 (1.88-21.01) 2.80 (0.80-9.75)	0.039 0.103 0.003 0.108	1 0.63 (0.24-1.66) 0.45 (0.15-1.38) 1.20 (0.52-2.77) 0.32 (0.09-1.14) 0.67 (0.14-3.24)	0.349 0.162 0.671 0.080 0.620

^*The rest of adverse effects did not show significant association (OR) with previous COVID-19, nor with 1st dose, neither with 2nd dose.